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912 The Journal of Thoracic and CardioBackground: Poor oxygenation might occur in transplanted lungs as a result of
reperfusion injury and lack of lymphatic drainage. Low central venous and pulmo-
nary capillary wedge pressures are advocated to reduce pulmonary edema and
maximize oxygenation but might adversely affect cardiac index, circulation, and
renal function.
Methods: Histories, intensive care unit charts, and donor data on 118 lung trans-
plantations performed between 1999 and 2002 were retrospectively assessed. Mul-
tiple logistic regression analysis was performed on donor, recipient, operative, and
intensive care unit parameters to determine the relationship of filling pressure
(central venous and pulmonary capillary wedge pressures) to prolonged mechanical
ventilation and outcome. The mean central venous pressure was used to divide
patients into high and low central venous pressure groups, which were then com-
pared to determine differences in outcome and complication rates.
Results: A high central venous pressure was found to be associated with prolonged
mechanical ventilation (odds ratio, 1.57; 95% confidence interval, 1.13-2.20; P 
.008). After removing the effect of poor myocardial function by excluding patients
with low cardiac index (2.2 L · min1 · m2) and high inotrope requirement (10
g/min), central venous pressure remained associated with prolonged mechanical
ventilation (odds ratio, 2.31; 95% confidence interval, 1.31-4.07; P  .004).
Duration of ventilation (P  .001), intensive care unit mortality (P  .02), hospital
mortality (P  .09), and 2-month mortality (P  .02) were higher in patients with
central venous pressures of greater than 7 mm Hg. There was no evidence of
complications caused by hypovolemia in the low (7 mm Hg) central venous
pressure group, who had lower inotrope requirements (P .02) and lower creatinine
levels (P  .013).
Conclusions: A high central venous pressure was associated with adverse outcomes
after lung transplantation.
Transplantation is an established treatment for end-stage pulmonaryvascular and parenchymal disease. Perhaps the most important factorcomplicating the early postoperative period is reperfusion pulmo-nary edema, which is reported in 10% to 35% of cases.1-4 Thetransplanted lung is at risk of this because of a lack of lymphaticdrainage and inflammatory insults, such as infection-aspiration in the
donor, direct pulmonary trauma, and inflammatory cytokine release associated with
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TXbrain death, explantation, and reperfusion.5,6 Although dis-
puted, preferential cardiac output through the first implanted
lung during bilateral sequential transplantation has also
been proposed as a risk factor for reperfusion injury.7,8
Thus, edema might occur through a combination of in-
creased hydrostatic forces and increased capillary perme-
ability.9,10
Protocols for routine postoperative care specify that
filling pressures, such as pulmonary capillary wedge
pressure (PCWP) and central venous pressure (CVP),
should be kept low to minimize reperfusion pulmonary
edema.11 A theoretical disadvantage is that this might
lead to hypovolemia, renal dysfunction, and increased
inotrope requirements. There is, however, no evidence
base to support this. The primary aim of our study was to
determine whether such a relationship existed and to
determine whether patients had evidence of complica-
tions arising from this relationship.
Methods
Patient Population
From the beginning of July 1999 to the end of June 2002, a total
of 128 lung transplantations were performed at the Alfred Hospi-
tal. Complete information was available for 118 of the patients: 61
bilateral sequential lung transplant recipients and 57 single lung
transplant recipients.
Primary Outcome
The primary outcome examined was prolonged mechanical venti-
lation (PMV), which is defined as the need for mechanical venti-
lation on the third postoperative day. Patients who were extubated
but needed reintubation before day 3 and patients who died before
day 3 were also included in the PMV group. Intensive care unit
(ICU) mortality, 30-day mortality, hospital mortality, and overall
survival time were noted. The mean CVP (7.2 mm Hg) for the
group was then used to divide patients into high (7 mm Hg) and
low (7 mm Hg) CVP groups to compare their outcomes.
Donor Factors
Donor assessment was according to previously published guide-
lines.12 Standard donor selection criteria were age less than 55
years, ABO compatibility, a smoking history of less than 20
pack-years, a clear chest radiograph, absence of chest trauma, no
TABLE 1. Multivariate analysis of factors associated with
prolonged mechanical ventilation for all patients
All Patients (n  118)
Odds ratio 95% CI P value
CVP (days 1–3) 1.57 1.13-2.20 .008
PaO2/FIO2 (day 1) 0.989 0.980-0.998 .020
APACHE II score 1.21 1.08-1.36 .001
CI, Confidence interval; CVP, central venous pressure; FIO2, fraction of
inspired oxygen.evidence of aspiration or chest sepsis, and a PaO2 of greater than
The Journal of Thoraci300 mm Hg. PaO2 was measured on 100% fraction of inspired
oxygen (FIO2) and 5 cm H2O positive end-expiratory pressure
(PEEP). There were 105 donors for 128 recipients. Of these, 13
were older than 55 years, and 3 had PaO2 values of less than 300
mm Hg. Lung procurement and preservation followed a standard
protocol, with cold modified Euro-Collins solution for antegrade
flushing. Prostacyclin (Flolan, Wellcome) was also infused at 40 to
80 ng · kg1 · min1 for approximately 10 minutes before cross-
clamping the pulmonary artery. Donor variables analyzed were
age, sex, PaO2, history of smoking, and inotrope use.
Recipient Factors
Recipient selection for transplantation was according to previously
published guidelines.13 Recipient factors analyzed were sex, age,
diagnosis, and preoperative creatinine level. Diagnoses were coded
as cystic fibrosis, primary pulmonary hypertension, interstitial lung
disease, chronic obstructive pulmonary disease, and “other” for the
remaining patients.
Operative Factors
The technical details of lung transplantation have been previously
described.14 A pulmonary artery flotation catheter (Edwards Life-
sciences, Irvine, Calif) was inserted in each recipient preopera-
tively to monitor cardiac output, pulmonary artery pressures, CVP,
and PCWP. This was then used to guide operative anesthetic
management and remained in situ in the ICU. Operative factors
analyzed were incidence and duration of cardiopulmonary bypass,
ischemic time for the organs, and procedure type (single-bilateral
transplantation). In cases in which double-lung transplantation was
undertaken, the mean ischemic time of the 2 lungs was analyzed.
ICU Factors
ICU management was aimed at ensuring the adequacy of end-organ
perfusion. Although maintaining low filling pressures (PCWP of10
mm Hg and CVP of 7 mm Hg) was usually a target, it was not
aggressively pursued. Inhaled nitric oxide (at 20 ppm) was used if
there was increasing pulmonary artery pressure or decreasing oxy-
genation. Independent lung ventilation and extracorporeal membrane
oxygenation were used if required. The immunosuppressive regimen
has been published previously.15 Maintenance comprised cyclospor-
ine (INN: ciclosporin; initially aiming for trough levels of 300-450
TABLE 2. Multivariate analysis of factors associated with
prolonged mechanical ventilation after exclusion of pa-
tients with low cardiac output or high inotrope dosage
Patients with cardiac index >2.2 L · min1 ·
m2 and inotropes <10 g/min (n  99)
Odds
ratio 95% CI P value
CVP (days 1-3) 2.31 1.31-4.07 .004
PaO2/FIO2 (day 1) 0.987 0.975-1.00 .044
APACHE II Score 1.16 0.99-1.35 .055
CI, Confidence interval; CVP, central venous pressure; FIO2, fraction of
inspired oxygen.g/L), azathioprine (1.5-2 mg · kg1 · d1), and prednisolone (0.15
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basis of known or suspected recipient and donor microbiology results.
Ganciclovir (initially at 10 mg · kg1 · d1) was used where indicated
as prophylaxis against cytomegalovirus.
ICU management variables were recorded for each 24-hour
period after the operation. Cardiovascular variables analyzed were
cardiac index (in liters per minute per meter squared) PCWP (in
millimeters of mercury), CVP (in millimeters of mercury), and
inotrope dosage. The mean value for day 1 and the mean value for
days 1 to 3 were included in the multivariate analysis. Inotrope
doses were recorded hourly in micrograms per minute. Epineph-
rine and norepinephrine doses were added together for the final
inotrope dose. Other vasoactive drugs, such as dopamine (n 11),
milrinone (n  2), dobutamine (n  2), and isoprenaline (n  1),
were rarely used and not included in the analysis. Respiratory
variables analyzed were worst PaO2/FIO2 ratio in each 24-hour
period, mean level of PEEP over each day, and duration of me-
chanical ventilation. PaO2/FIO2 ratios were recorded independently
from those used to calculate the Acute Physiology and Chronic
Health Evaluation (APACHE II) score. Renal factors included
worst creatinine level during ICU stay and mean fluid balance over
the first 3 days. The APACHE II scores for each patient and
APACHE II–derived predicted mortality were also recorded.
Statistical Analysis
All analyses were performed with SAS version 8.2 software (SAS
Institute Inc, Cary, NC). Each variable was analyzed as a separate
risk factor for the outcome by comparing patients who required
TABLE 3. Comparison of patients with CVPs of 7 mm Hg o
Donor, recipient, and operative
variables
CVP <7 m
(n  5
Donor factors
Age (y) 38 1
PaO2 (mm Hg) 469 1
Female sex 41% (n
Smoking donor 57% (n
Donor taking inotropes 80% (n
Recipient factors
Diagnosis
CF (mean CVP  7  3) 30% (n
COPD (mean CVP  7  2) 59% (n
PPH (mean CVP  11  4) 0% (n
ILD (mean CVP  7  2) 11% (n
Other (mean CVP  10  2) 0% (n
Female sex 34% (n
Age (y) 45 1
Preoperative creatinine (mol/L) 67 2
Operative factors
Single lung transplantation 57% (n
Proportion requiring CPB 2% (n
Duration of CPB (min) 149 0
Ischemic time (min) 374 1
Prevalence data are presented as a percentage of the total in each gro
pressure; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disea
cardiopulmonary bypass.PMV with those who did not.
914 The Journal of Thoracic and Cardiovascular Surgery ● ApriAll data were assessed for normality and log-transformed
where appropriate. Univariate analysis was conducted by Student
t tests, 2 tests for equal proportion, and Wilcoxon rank-sum tests
where appropriate. Multivariate models were constructed by a
stepwise selection procedure and then validated by a backward
elimination procedure. All donor, recipient, operative, and ICU
variables were used to build a multivariate model to determine
factors associated with PMV. The inclusion of statistically non-
significant but clinically relevant variables, such as the diagnostic
categories, did not alter the final model. A final validation process
involving an assessment of clinical plausibility was also incorpo-
rated. Information is presented as means with SDs for normally
distributed data and medians with interquartile ranges for nonpara-
metric data.
Results
Complete information was available for 118 of the 128 lung
transplantations performed at the Alfred Hospital from the
beginning of July 1999 to the end of June 2002. Twenty-
seven patients needed PMV. This included 4 patients who
were extubated but required reintubation before day 3 and 2
patients who died before day 3. Of the missing 10 patients,
3 required PMV. All 3 left the ICU alive, but 1 died before
leaving the hospital.
Multiple logistic regression analysis was used to incor-
porate factors associated with PMV at a univariate level into
s with patients with CVPs of greater than 7 mm Hg
CVP >7 mm Hg
(n  62) P value
35  15 .22
462 90 .21
40% (n 25) .78
47% (n 29) .43
77% (n 48) .62
31% (n 19) .67
47% (n 29) .26
5% (n 3) .28
13% (n 8) .66
5% (n 3) .28
52% (n 32) .12
43  14 .23
73  28 .44
40% (n 25) .11
13% (n 8) .09
180  69 .17
365 133 .40
ntinuous variables are presented as means  SD. CVP, Central venous
PH, primary pulmonary hypertension; ILD, interstitial lung disease; CPB,r les
m Hg
6)
4
22
23)
32)
45)
17)
33)
0)
6)
0)
19)
6
2
32)
1)
33
up. Co
se; Pa multivariate model. This confirmed that a high CVP (over
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significant factors were a high APACHE II score (P .001)
and a low PaO2/FIO2 ratio on day 1 (P  .02; Table 1).
Donor, recipient, and operative factors were not related to
PMV. Although there was a tight correlation between the
CVP and PCWP (R  0.75, P  .0001), PCWP was not an
independent predictor of PMV in the mechanical ventilation
analysis. All further analyses were done with the CVP. The
Figure 1. Histogra
TABLE 4. Comparison of outcomes between patients with C
7 mm Hg
CVP <7
(n 
Prolonged mechanical ventilation 4% (n
Duration of ICU stay (d) 3 (2
Duration of hospital stay: survivors (d) 19 (1
ICU mortality 0% (n
Hospital mortality 4% (n
Prevalence data are presented as a percentage of the total in each grou
Central venous pressure; ICU, intensive care unit.mean CVP (7.2 mm Hg) for the group was then used to
The Journal of Thoracidivide patients into low (7 mm Hg) and high (7 mm Hg)
CVP groups to compare their outcomes.
The data were analyzed further to allow for the effect of
factors that might influence the CVP, including mechanical
ventilation, vasoconstrictor inotropes, and low cardiac out-
put. PEEP was already included in the multivariate analysis
as a significant variable in its own right. Despite a statisti-
cally significant difference in the level of PEEP between the
ventilation hours.
of 7 mm Hg or less and patients with CVPs of greater than
Hg CVP >7 mm Hg
(n  62) P value
40% (n 25) .001
5 (3-7) .001
27 (16-46) .02
8% (n 5) .02
13% (n 8) .09
ntinuous variables are presented as medians (interquartile ranges). CVP,VPs
mm
56)
 2)
-3)
6-25)
 0)
 2)
p. Cogroups (4.8 2.2 cm H2O vs 6.6 2.9 cm H2O, P .003),
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After excluding 19 patients who had both a cardiac index of
2.2 L · min1 · m2 or less (10th percentile) and inotropes
of greater than 10 g/min (90th percentile), the CVP (P 
.004) and PaO2/FIO2 ratio (P  .044) remained significantly
associated with PMV (Table 2). The APACHE II score was
no longer significant, but the CVP increased in significance
(P  .004).
There were no differences in recipient, donor, or opera-
tive factors between the 2 groups (Table 3). More patients in
the high CVP group needed PMV (P  .001). The distri-
bution curve of duration of ventilation for the high and low
CVP groups is shown in Figure 1. Of the 27 patients who
needed PMV, 25 had CVPs of greater than 7 mm Hg. The
high CVP group had greater ICU mortality (P  .02) and
longer ICU stays (P  .001), and survivors spent longer in
the hospital (P  .02). All 5 ICU deaths were in patients
with CVPs of greater than 7 mm Hg (Table 4). Of those who
Time
Deaths
2 months 1/56 
6 months 4/56 
1 year 9/56
4 years 26/30
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Figure 2. Kaplan-Meier curve for high and low CVP gro
(P  .02) and higher mortality at 2 months (P  .02), the
with low CVP (P  .7).died before 2 months, 10 of 11 patients had CVPs of greater
916 The Journal of Thoracic and Cardiovascular Surgery ● Aprithan 7 mm Hg, and all required PMV. Although patients
with high CVPs had higher mortality at 2 months (P .02),
their overall survival was not significantly different from
that of those with low CVPs (P  .7, Figure 2).
Patients with high CVPs had higher APACHE II scores (P
 .004), higher inotrope requirements (P  .04), and higher
creatinine levels (P  .001). There was a trend toward worse
oxygenation (day 1, P  .06; day 2, P  .05) in those with
high CVPs. There was no difference in the fluid balance or
cardiac index between the 2 groups (Table 5).
Discussion
Low filling pressures (CVP and PCWP) are routinely advo-
cated by most transplant centers to minimize pulmonary
edema caused by reperfusion injury.11 Despite publication
of risk factors for reperfusion injury,16 PMV,17,18 and ad-
verse early outcomes19 after lung transplantation, the influ-
ence of CVP or PCWP on outcome has not been clearly
Deaths
P > 7 mmHg pValue
10/62 0.02
12/62 0.10
14/62 0.51
26/33 0.62
rve for 
 Groups
36 48
CVP >
7mmHg
(n=62)
CVP <
7mmHg
(n=56)
hile patients with high CVPs had higher ICU mortality
rall survival was not significantly different from thoseCV
r Cu
 CVP
hs
ups. W
ir oveestablished.
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PMV. Our study is a retrospective analysis. It cannot defin-
itively demonstrate causal relationships or define the effect
of interventions. Patients with CVPs of greater than 7 mm
Hg had longer lengths of stay (in ICU and in hospital) and
had higher mortality (in ICU and at discharge from hospi-
tal). Ten of the 11 early deaths (2 months) occurred in
patients who had both high CVPs and needed PMV. How-
ever, there was no evidence of decreased long-term survival
in patients with high CVPs.
Although CVP and PCWP are commonly used as indi-
cators of volume status and cardiac preload, they are influ-
enced by many factors.20 We have attempted to eliminate
the effect of poor myocardial function on the CVP by
repeating the analysis after exclusion of patients with low
cardiac indices or patients receiving high doses of epineph-
rine, norepinephrine, or both. Having done this, the rela-
tionship of CVP to PMV remained significant. The con-
founding effect of mechanical ventilation on the CVP
cannot be fully excluded, but the degree is variable depend-
ing on the mode of ventilation, the level of PEEP, and the
compliance of the respiratory system.21-23 To take this into
account, PEEP was included in the multivariate analysis and
was not independently associated with PMV. Its inclusion
also did not alter the association between the CVP and
PMV.
Preoperative and postoperative pulmonary hypertension
have been associated with reperfusion injury and worse
TABLE 5. Comparison of patients with CVPs of 7 mm Hg o
ICU/physiologic variables
APACHE II score
APACHE II predicted mortality
Cardiovascular days 1-3
CVP (mm Hg)
PCWP (mm Hg)
Cardiac index (L · min1 · m2)
Inotrope dose (g/min)
Respiratory
Duration of ventilation (h)
Level of PEEP while ventilated (cm H2O)
PaO2/FIO2 ratio day 1
PaO2/FIO2 ratio day 2
Single-lung ventilation
ECMO
Nitric oxide
Renal
Highest postoperative creatinine in ICU (mol/L)
Incidence of dialysis
Fluid balance days 1-3 (mL)
Prevalence data are presented as a percentage of the total in each group
range) as appropriate. CVP, Central venous pressure; ICU, intensive care
pressure; FIO2, fraction of inspired oxygen; ECMO, extracorporeal membraoutcome after lung transplantation.1,7,19,24,25 Pulmonary ar-
The Journal of Thoraciterial hypertension and right ventricular dysfunction might
in part explain the association between the CVP and PMV
in our study. Unfortunately, because of inconsistencies in
recording, we were not able to include direct measurements
of pulmonary artery pressure in our analysis. However, the
tight correlation between the CVP and PCWP suggests that
there might be many cases in which pulmonary hyperten-
sion is secondary to raised left atrial pressure rather than a
primary problem with the pulmonary vasculature.
Although numerous articles26-29 have reported advan-
tages of the pulmonary vasodilator nitric oxide, a recent
randomized trial30 did not show significant benefit in pre-
vention of reperfusion injury. However, the use of nitric
oxide was not targeted to patients with pulmonary hyper-
tension and increased CVP.
The association between CVP and PMV, even after
correcting for mechanical ventilation, poor cardiac function,
and high inotrope use, raises speculation as to whether
outcome in patients with high CVPs might have been im-
proved by more aggressive application of pulmonary vaso-
dilators, fluid restriction, and diuretics. Demonstrating a
reduction in CVP in response to these interventions might
identify those likely to obtain the greatest benefit.
There was no evidence that patients with lower CVPs
had complications related to hypovolemia. Quite the re-
verse, patients with a high CVP had increased inotrope
requirements and higher serum creatinine levels. This and
s with patients with CVPs of greater than 7 mm Hg
CVP <7 mm Hg CVP >7 mm Hg P value
14 5 18  7 .004
15% 11% 23% 20% .02
5.0 1.5 9.1 1.4 .001
8.4 2.2 11.6  2.1 .001
3.6  0.5 3.4 0.67 .12
1.3 (0.3-2.8) 2.4 (0.3-5.7) .04
7 (1-16) 25 (6-97) .001
4.8  2.2 6.6 2.9 .003
209 101 180 110 .06
272 102 233 92 .05
2% (n  1) 13% (n  8) .03
0% (n  0) 5% (n  3) .09
9% (n  5) 19% (n  12) .11
78 28 108  58.3 .001
5% (n  3) 10% (n  6) .47
(540 to1761) 1365 (9 to2700) .32
tinuous variables are presented as means  SD or median (interquartile
PCWP, pulmonary capillary wedge pressure; PEEP, peak end-expiratory
ygenation.r les
780
. Con
unit;the trend toward better oxygenation in the low CVP group
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TXsupports the present policy of our unit in aiming for low
filling pressures in the early postoperative period.
In conclusion, our study confirms that there is a relation-
ship between a high CVP and an adverse outcome after lung
transplantation. This is independent of cardiac function and
not caused by the presence of mechanical ventilation. We
could find no evidence of complications related to hypovo-
lemia in patients with low CVPs. The CVP remains both a
useful hemodynamic marker of the patient’s status and a
prognostic marker for PMV and poor outcome after lung
transplantation. Whether interventions to manipulate CVP
affect patient outcome is yet to be determined.
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